Exhibit 99.1

CardioDynamics BioZ Monitoring Reduces Incidence of Low Blood Pressure by 52% in
Women Undergoing Cesarean Section

PR Newswire -- May 9, 2005

    STUDY PRESENTED AT THE 37TH ANNUAL SOCIETY FOR OBSTETRICS ANESTHESIA AND
                                  PERINATOLOGY

SAN DIEGO, May 9 /PRNewswire-FirstCall/ -- CardioDynamics (Nasdaq:
CDIC), the innovator and leader of Impedance Cardiography (ICG)
technology, today announced the presentation of a BioZ ICG study at the
Society for Obstetrics Anesthesia and Perinatology 37th Annual Meeting
held May 4-7, 2005, in Palm Desert, CA. The study, conducted by
researchers from the University of Texas Southwestern Medical Center at
Dallas, determined the incidence of hypotension (low blood pressure) was
reduced by 52% when the Company's BioZ monitored cardiac output and
systemic vascular resistance (SVR) following spinal anesthesia for
cesarean section. Early detection of changes in these parameters allowed
the clinicians to treat with drugs to counteract the potentially harmful
effects of hypotension.

Shiv Sharma, M.D., Professor, Department of Anesthesiology/Pain
Management, UTSM Center at Dallas, stated, "Up to 25% of the four
million births per year in the United States are delivered by cesarean
section. Hypotension occurs in up to 70% of women undergoing cesarean
section following spinal anesthesia. Low cardiac output and/or low
systemic vascular resistance cause hypotension. Early treatment of a
drop in systemic vascular resistance, as obtained by the BioZ system,
significantly minimized the incidence of hypotension without
compromising the welfare of the fetus."

"This study identifies yet another application for our ICG technology,"
stated Michael K. Perry, CardioDynamics' Chief Executive Officer.
"Invasive methods are not an option in this patient group, and there is
a clear need for physicians to have access to continuous blood flow data
in order to provide early assessment and treatment without risk to the
mother or her baby."

About CardioDynamics:

CardioDynamics (Nasdaq: CDIC), the ICG Company, is the innovator and
leader of breakthrough medical technology called Impedance Cardiography
(ICG). The Company develops, manufactures and markets noninvasive
diagnostic and monitoring technologies and electrodes. The Company's ICG
Systems are being used by physicians around the world to help battle the
number one killer of men and women -- cardiovascular disease. Partners
include GE Healthcare and Philips Medical Systems. For additional
information, please refer to the company's Web site at www.cdic.com.



Forward-Looking (Safe Harbor) Statement:

Except for the historical and factual information contained herein, this
press release contains forward-looking statements, such as potential
growth rates, success of clinical studies, the accuracy of which is
necessarily subject to uncertainties and risks including the Company's
primary dependence on the BioZ product line, and various uncertainties
characteristic of early growth companies, as well as other risks
detailed in the Company's filings with the SEC, including its 2004 Form
10-K/A. The Company does not undertake to update the disclosures
contained in this press release.

SOURCE  CardioDynamics
    -0-                             05/09/2005
    /CONTACT:  Investor Relations, Bonnie Ortega, ext. 1005,
bortega@cardiodynamics.com, or Media Relations, Irene Paigah, ext. 1012,
ipaigah@cardiodynamics.com, both of CardioDynamics, +1-888-522-2342/
    /Web site:  http://www.cdic.com